Atropine Sulfate Market Trends

Growth Drivers

• The steady growth of the APAC market over the years
  Asia Pacific (APAC) healthcare market is displaying steady growth with no signs of stopping as a result of revised and improved access to healthcare facilities amidst increased government and private investments. Further, the increasing government initiatives to improve the healthcare market in Asia are responsible for escalating the atropine sulfate market growth. Technological contributions are also leading to progress, such as digital medical records, telemedicine, robot nurses, and more. Advanced technologies have changed the condition of hospitals and medical services. Cumulatively, this has resulted in a rise in the demand for healthcare services and pharmaceutical products in the Asia Pacific region. This factor is anticipated to lead to the growth of the atropine sulfate market at a significant rate in the coming years. 

• Increase in the rate of surgical services
  Surgical services are recognized to be an essential component of the public health system. Surgical services occur in every setting, from developed countries to underdeveloped countries, and the worldwide necessity of surgeries has increased greatly with the shifting patterns of disease. Little is known about the actual worldwide need and availability of surgical volumes since only circumstantial evidence exists. However, surgery is anticipated to have an increased role in public health owing to epidemiological transition. The worldwide volume of surgery is large and increasing along with high number of deaths and major surgical procedures rates. With the increasing demand for surgical services, the atropine sulfate market growth of the atropine sulfate is anticipated to flourish in the coming years.  

Challenges

• Falling demand due to lethal side effects
  Association of various lethal side-effects and contraindications of atropine sulfate has hampered with the market growth of the drug. Adverse reactions of atropine include ventricular fibrillation (a life-threatening situation with inadequate heart rhythm), ventricular tachycardia (a condition in which the ventricles beat very quickly), extreme confusion, photophobia, and others. Additionally, it contraindicated in people with glaucoma, pyloric stenosis, or benign prostatic hyperplasia. In spite of all the advantages, contraindications and adverse effects of the atropine sulfate are threatening to the lives of patients. This factor is estimated to restrict the growth of the atropine sulfate market over the forecast period.

• Leaner demand and negative growth in past to restrict market growth
  Atropine was earlier included in international resuscitation guidelines for use in cardiac arrest but was later removed in 2010 due to a lack of effectiveness. Additionally, the low cost of production and less profit margin led to a shortage of atropine sulfate supply globally. Many companies shut down their production of atropine due to incurred losses. This factor is predicted to hamper the future growth of the market.